Table 3 Changes in laboratory data from baseline, and diuretic use after 1 year of tolvaptan treatment
From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites
(n = 37) | Pretreatment | Post-treatment | p-value |
|---|---|---|---|
Diuretic | |||
Furosemide dose (mg/day) | 20 (0–80) | 20 (0–80) | 0.28 |
Spironolactone dose (mg/day) | 50 (0–150) | 37.5 (0–150) | 0.50 |
Laboratory data | |||
Albumin (g/dL) | 2.6 (1.7–4.2) | 3.1 (1.5–4.4) | < 0.01 |
Total bilirubin (mg/dL) | 2.0 (0.4–21.7) | 1.5 (0.3–8.2) | 0.01 |
Aspartate aminotransferase (U/L) | 42 (13–171) | 34 (15–701) | 0.09 |
Alanine aminotransferase (U/L) | 29 (7–144) | 20 (9–255) | 0.14 |
γ-Glutamyl transpeptidase (U/L) | 48 (9–229) | 40 (12–285) | 0.52 |
Platelet count (×104/μL) | 7.6 (1.5–23.9) | 7.7 (1.6–23.6) | 0.64 |
Hematocrit (%) | 28.6 (24.2–37.3) | 32.0 (18.8–40.7) | 0.06 |
Prothrombin time (PT%) | 54.5 (19.5–90.3) | 60.4 (19.4–89.4) | 0.09 |
PT/INR | 1.32 (0.98–2.84) | 1.26 (1.01–2.70) | 0.02 |
Ammonia (μg/dL) | 85 (25–269) | 67 (12–212) | < 0.01 |
α-fetoprotein (ng/mL) | 4 (1–210) | 3 (1–17,734) | 0.79 |
Des-gamma-carboxy (mAU/mL) | 27 (3–4994) | 27 (8–40,510) | 0.53 |
Blood urea nitrogen (mg/dL) | 23.2 (6.0–63.3) | 25.4 (6.0–75.2) | 0.99 |
Creatinine (mg/dL) | 1.04 (0.44–3.30) | 1.16 (0.50–2.48) | 0.09 |
eGFR (mL/min/1.73 m2) | 49.5 (16.8–107.2) | 42.9 (15.3–136.3) | 0.42 |
Serum sodium (mEq/L) | 137 (122–145) | 138 (123–144) | 0.63 |
Modified Child-Pugh (CP) score | 11 (8–13) | 10 (6–13) | < 0.01 |
MELD score | 12 (2–29) | 12 (3–22) | 0.13 |